The development of new chemical drugs is an extremely difficult and complex process, involving basic research and confirmation of therapeutic targets, the establishment of biological models and methodologies for in vitro and in vivo screening of lead compounds, the relationship between pharmacokinetic characteristics and targets, possible differences between preclinical safety evaluation and human use, and whether animal pathological models reflect the etiology of human diseases. The entire process is exceedingly lengthy and fraught with risks. The vast majority of lead compounds are eliminated in the later stages of development due to unsatisfactory efficacy, severe toxic and side effects, or lack of significant advantages and improvements compared to already marketed drugs. How can a rapid and effective comprehensive early evaluation system be established to detect and predict the potential safety and possible clinical efficacy of biologically active lead compounds at an early stage? How can scientific evidence be provided to help new drug R&D scientists and managers decide which lead compounds should advance to preclinical and subsequent clinical trial stages to minimize development risks? These are currently major challenges in the field of international new drug R&D.

The company pioneered the core technology system of the "Integrated Drug Discovery and Early Evaluation Platform Based on Chemical Genomics" internationally. Chemical genomics technology utilizes a large amount of known gene expression data and functional significance analysis. Through parallel correlation studies of the effects of various known compounds (successful drugs or failed drugs) and any new compounds on whole-genome expression, it evaluates and predicts the possible molecular pharmacology and toxicology of new compounds, continuously optimizes the structure of candidate compounds, and enables lead compounds with the best comprehensive evaluation results to advance to the next stage of development, which holds significant value in reducing new drug development risks. This aligns precisely with the Critical Path Initiative advocated by the U.S. FDA to promote the success rate of innovative drug development.

With advancements in the field, this platform system has incorporated AI technology for assistance and integrated the company's comprehensive clinical development strategy. By supporting early risk prediction, it reduces clinical development risks and enhances clinical development efficiency. The internationally leading and continuously evolving core technology system highly reflects the company's core competitiveness, providing robust technical support for enhancing sustained independent innovative drug R&D capabilities and exploring an international path for new drug development suited to national conditions and resources.